Measurable residual disease (MRD) can predict disease progression in patients who have acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML). A new review ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback